Published in Int Clin Psychopharmacol on September 01, 2010
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry (2014) 1.39
Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder - evidence from clinical trials. Wien Med Wochenschr (2010) 0.99
Lavender and the nervous system. Evid Based Complement Alternat Med (2013) 0.92
Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One (2013) 0.89
Effects of Silexan on the serotonin-1A receptor and microstructure of the human brain: a randomized, placebo-controlled, double-blind, cross-over study with molecular and structural neuroimaging. Int J Neuropsychopharmacol (2014) 0.89
The prevalence and burden of subthreshold generalized anxiety disorder: a systematic review. BMC Psychiatry (2014) 0.88
The metabolic responses to aerial diffusion of essential oils. PLoS One (2012) 0.79
Practical clinical trials in psychopharmacology: a systematic review. J Clin Psychopharmacol (2015) 0.77
Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr (2015) 0.76
Evaluating the effects of diffused lavender in an adult day care center for patients with dementia in an effort to decrease behavioral issues: a pilot study. J Drug Assess (2017) 0.75
No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination. Drugs R D (2014) 0.75
Lavender oil suppresses indoleamine 2,3-dioxygenase activity in human PBMC. BMC Complement Altern Med (2014) 0.75
Exploring Pharmacological Mechanisms of Lavender (Lavandula angustifolia) Essential Oil on Central Nervous System Targets. Front Pharmacol (2017) 0.75
Mood Therapeutics: Novel Pharmacological Approaches for Treating Depression. Expert Rev Clin Pharmacol (2016) 0.75
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet (2008) 10.52
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet (2008) 4.78
Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ (2003) 3.78
Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol (2010) 2.74
The diagnosis and treatment of generalized anxiety disorder. Dtsch Arztebl Int (2013) 2.73
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry (2008) 2.64
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry (2007) 2.40
Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry (2009) 2.17
Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry (2002) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry (2007) 2.05
Multivariate deformation-based analysis of brain atrophy to predict Alzheimer's disease in mild cognitive impairment. Neuroimage (2007) 2.03
Measurement of basal forebrain atrophy in Alzheimer's disease using MRI. Brain (2005) 2.03
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry (2005) 1.98
Maternally derived microduplications at 15q11-q13: implication of imprinted genes in psychotic illness. Am J Psychiatry (2011) 1.94
Integration of fMRI and simultaneous EEG: towards a comprehensive understanding of localization and time-course of brain activity in target detection. Neuroimage (2004) 1.84
Prefrontal transcranial direct current stimulation changes connectivity of resting-state networks during fMRI. J Neurosci (2011) 1.81
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Genomewide association analysis followed by a replication study implicates a novel candidate gene for neuroticism. Arch Gen Psychiatry (2008) 1.75
Factor structure and external validity of the PANSS revisited. Schizophr Res (2005) 1.74
Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One (2009) 1.71
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry (2012) 1.69
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry (2003) 1.66
Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem (2005) 1.64
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry (2002) 1.63
Depression-related variation in brain morphology over 3 years: effects of stress? Arch Gen Psychiatry (2008) 1.61
The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry (2010) 1.61
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
Larger amygdala volumes in first depressive episode as compared to recurrent major depression and healthy control subjects. Biol Psychiatry (2003) 1.55
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry (2012) 1.55
Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: a 3-year prospective magnetic resonance imaging study. J Psychiatry Neurosci (2008) 1.53
Multivariate network analysis of fiber tract integrity in Alzheimer's disease. Neuroimage (2006) 1.52
Response and remission criteria in major depression--a validation of current practice. J Psychiatr Res (2010) 1.52
Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic Biol Med (2005) 1.51
Syndromes and phenomenological subtypes underlying acute mania: a factor analytic study of 576 manic patients. Am J Psychiatry (2002) 1.51
Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract (2012) 1.49
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry (2013) 1.48
Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry (2004) 1.48
Neuroanatomy of "hearing voices": a frontotemporal brain structural abnormality associated with auditory hallucinations in schizophrenia. Cereb Cortex (2004) 1.46
Psychosis susceptibility gene ZNF804A and cognitive performance in schizophrenia. Arch Gen Psychiatry (2010) 1.46
Age-related cortical grey matter reductions in non-demented Down's syndrome adults determined by MRI with voxel-based morphometry. Brain (2004) 1.45
Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol (2002) 1.44
Kinematic analysis of the effects of donepezil hydrochloride on hand motor function in patients with Alzheimer dementia. J Clin Psychopharmacol (2003) 1.43
Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis (2008) 1.42
Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project. J Clin Psychiatry (2010) 1.41
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. World J Biol Psychiatry (2002) 1.38
Enlargement of the amygdala in patients with a first episode of major depression. Biol Psychiatry (2002) 1.38
Ethical aspects of publishing. World J Biol Psychiatry (2006) 1.37
Early recognition and disease prediction in the at-risk mental states for psychosis using neurocognitive pattern classification. Schizophr Bull (2011) 1.36
Reduced hippocampal volume correlates with executive dysfunctioning in major depression. J Psychiatry Neurosci (2006) 1.35
Processing of temporal information and the basal ganglia: new evidence from fMRI. Exp Brain Res (2002) 1.35
Early detection and secondary prevention of psychosis: facts and visions. Eur Arch Psychiatry Clin Neurosci (2004) 1.34
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry (2013) 1.34
Use of brief depression screening tools in primary care: consideration of heterogeneity in performance in different patient groups. Gen Hosp Psychiatry (2004) 1.34
Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition. Depress Anxiety (2007) 1.32
Hyperforin--a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J (2007) 1.31
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
White matter microstructure underlying default mode network connectivity in the human brain. Neuroimage (2009) 1.29
Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry (2002) 1.28
Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem (2004) 1.28
Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal (2007) 1.28
Personality and attempted suicide. Analysis of anger, aggression and impulsivity. J Psychiatr Res (2009) 1.26
Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol (2003) 1.24
Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) (2008) 1.23
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci (2009) 1.23
Is the PANSS used correctly? a systematic review. BMC Psychiatry (2011) 1.22
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res (2010) 1.22
Functional connectivity bias of the orbitofrontal cortex in drug-free patients with major depression. Biol Psychiatry (2010) 1.22
Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry (2002) 1.19
Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry (2007) 1.19
Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome. Am J Psychiatry (2003) 1.19
Single nucleotide polymorphism and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene in suicide victims. Biol Psychiatry (2004) 1.17
Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem (2007) 1.16
Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther (2004) 1.16
The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. J Neurosci (2011) 1.14
Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord (2008) 1.13
Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol (2002) 1.13
Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal (2012) 1.12
Childhood stress, serotonin transporter gene and brain structures in major depression. Neuropsychopharmacology (2010) 1.12
Functional connectivity of emotional processing in depression. J Affect Disord (2011) 1.11
Reduced early auditory evoked gamma-band response in patients with schizophrenia. Biol Psychiatry (2009) 1.11
Failure to replicate effect of Kibra on human memory in two large cohorts of European origin. Am J Med Genet B Neuropsychiatr Genet (2008) 1.11
Sound level dependence of the primary auditory cortex: Simultaneous measurement with 61-channel EEG and fMRI. Neuroimage (2005) 1.11
Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol Res (2007) 1.11
Neuropsychological profiles in different at-risk states of psychosis: executive control impairment in the early--and additional memory dysfunction in the late--prodromal state. Schizophr Bull (2010) 1.10
Screening for depression in primary care: will one or two items suffice? Eur Arch Psychiatry Clin Neurosci (2004) 1.10
Structural correlates of psychopathological symptom dimensions in schizophrenia: a voxel-based morphometric study. Neuroimage (2007) 1.10
Analysis of tryptophan hydroxylase I and II mRNA expression in the human brain: a post-mortem study. J Psychiatr Res (2005) 1.10
World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry (2006) 1.10
Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis (2009) 1.09
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol (2009) 1.09
Tocotrienols: constitutional effects in aging and disease. J Nutr (2005) 1.09
A large replication study and meta-analysis in European samples provides further support for association of AHI1 markers with schizophrenia. Hum Mol Genet (2010) 1.08
Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients. Drug Alcohol Depend (2008) 1.08